Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage

Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that the United States Food and Drug Administration has granted clearance for Athenex Pharmaceutical Division to import Potassium Chloride Injection Concentrate (2 mEq/mL) in response to a national drug shortage of that product.

As quoted in the press release:

This FDA clearance allows APD to import Potassium Chloride Injection Concentrate on a temporary basis or for the duration of the shortage.

Jeffrey Yordon, Athenex’s Chief Operating Officer and President of Athenex’s Pharmaceutical Division, stated, “Potassium Chloride is currently on the drug shortage list of the FDA. We are happy to help provide a solution to the current shortage as we remain focused on developing novel therapies for the treatment of cancer.” The importation of Potassium Chloride Injection began in August, 2018 and is currently helping supply the US market demand.

Click here to read the full press release.